Xiu L. Zhu - Publications

RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

Journal: American journal of hematology

Published: February 03, 2026

Influence of lymphadenectomy extent on the efficacy of immunotherapy in recurrent gastric cancer patients.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 16, 2025

Multi-institutional assessment of HER2 immunohistochemistry in gastric and esophagogastric junction cancer.

Journal: iScience

Published: June 11, 2025

Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study.

Journal: Oncology letters

Published: October 15, 2024

Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer.

Journal: Cell death & disease

Published: August 28, 2024

Molecular Profiling of Germline Variants in the DNA Mismatch Repair Genes in Chinese Colorectal Cancer Patients.

Journal: Genetics research

Published: August 22, 2024

Clinicopathological features and prognostic significance of TAF1L in gastric cancer.

Journal: BMC gastroenterology

Published: July 15, 2024

Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment.

Journal: Cancer research

Published: June 20, 2024

Development and external validation of MRI-based RAS mutation status prediction model for liver metastases of colorectal cancer.

Journal: Journal of surgical oncology

Published: October 05, 2023

Pulmonary Salivary Gland Tumor, Mucoepidermoid Carcinoma: A Literature Review.

Journal: Journal of oncology

Published: March 27, 2022

Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.

Journal: Nature communications

Published: March 09, 2022

Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy.

Journal: Translational cancer research

Published: December 26, 2021